4SC announced today that the scheduled Data Safety Monitoring Board ("DSMB") had identified no safety concerns with the on-going RESMAIN pivotal trial Cutaneous TCell Lymphoma ("CTCL") and recommended the study should continue as planned. With top-line data from RESMAIN for resminostat and first interim data from SENSITIZE for 4SC-202 in melanoma expected in H1/2019 and H2/2018 respectively, there is plenty to drive value over the next 6-18 months. We reiterate our OUTPERFORM recommendation a
31 Jan 2018
Pivotal trial passes first safety hurdle
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Pivotal trial passes first safety hurdle
4SC announced today that the scheduled Data Safety Monitoring Board ("DSMB") had identified no safety concerns with the on-going RESMAIN pivotal trial Cutaneous TCell Lymphoma ("CTCL") and recommended the study should continue as planned. With top-line data from RESMAIN for resminostat and first interim data from SENSITIZE for 4SC-202 in melanoma expected in H1/2019 and H2/2018 respectively, there is plenty to drive value over the next 6-18 months. We reiterate our OUTPERFORM recommendation a